Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Rgenix Inc.
DescriptionCombination of two mAbs
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsTreat triple negative breast cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today